Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies

Susanne Eriksson(Karolinska Institutet), Erin H. Graf(University of Pennsylvania), Viktor Dahl(Karolinska Institutet), Matthew C. Strain(VA San Diego Healthcare System), Steven A. Yukl(San Francisco VA Medical Center), S. E. Lysenko(University of Pennsylvania), Ronald J. Bosch(Harvard University Press), Jun Lai(Johns Hopkins University), Stanley Chioma(Johns Hopkins Medicine), Fatemeh Emad(Johns Hopkins Medicine), Mohamed Abdel‐Mohsen(University of California, San Francisco), Rebecca Hoh(University of California, San Francisco), Frederick Hecht(University of California, San Francisco), Peter W. Hunt(University of California, San Francisco), Ma Somsouk(University of California, San Francisco), Joseph K. Wong(University of California, San Francisco), Rowena Johnston(American Foundation for AIDS Research), Robert F. Siliciano(Johns Hopkins University), Douglas D. Richman(VA San Diego Healthcare System), Una O’Doherty(University of Pennsylvania), Sarah Palmer(Swedish Institute), Steven G. Deeks(University of California, San Francisco), Janet D. Siliciano(Johns Hopkins University)
PLoS Pathogens
February 14, 2013
Cited by 577Open Access
Full Text

Abstract

HIV-1 reservoirs preclude virus eradication in patients receiving highly active antiretroviral therapy (HAART). The best characterized reservoir is a small, difficult-to-quantify pool of resting memory CD4(+) T cells carrying latent but replication-competent viral genomes. Because strategies targeting this latent reservoir are now being tested in clinical trials, well-validated high-throughput assays that quantify this reservoir are urgently needed. Here we compare eleven different approaches for quantitating persistent HIV-1 in 30 patients on HAART, using the original viral outgrowth assay for resting CD4(+) T cells carrying inducible, replication-competent viral genomes as a standard for comparison. PCR-based assays for cells containing HIV-1 DNA gave infected cell frequencies at least 2 logs higher than the viral outgrowth assay, even in subjects who started HAART during acute/early infection. This difference may reflect defective viral genomes. The ratio of infected cell frequencies determined by viral outgrowth and PCR-based assays varied dramatically between patients. Although strong correlations with the viral outgrowth assay could not be formally excluded for most assays, correlations achieved statistical significance only for integrated HIV-1 DNA in peripheral blood mononuclear cells and HIV-1 RNA/DNA ratio in rectal CD4(+) T cells. Residual viremia was below the limit of detection in many subjects and did not correlate with the viral outgrowth assays. The dramatic differences in infected cell frequencies and the lack of a precise correlation between culture and PCR-based assays raise the possibility that the successful clearance of latently infected cells may be masked by a larger and variable pool of cells with defective proviruses. These defective proviruses are detected by PCR but may not be affected by reactivation strategies and may not require eradication to accomplish an effective cure. A molecular understanding of the discrepancy between infected cell frequencies measured by viral outgrowth versus PCR assays is an urgent priority in HIV-1 cure research.


Related Papers

No related papers found

Powered by citation graph analysis